Serotonin-2 Receptor Agonists Produce Anti-inflammatory Effects through Functionally Selective Mechanisms That Involve the Suppression of Disease-Induced Arginase 1 Expression

Thomas W. Flanagan, Timothy P. Foster, Thomas E. Galbato, Pek Yee Lum, Brent Louie, Gavin Song, Adam L. Halberstadt, Gerald Billac, Charles D. Nichols

ACS Pharmacology & Translational Science · 2024 · 18 citations · 42 references

DOIFull text

Open access

Concepts

Abstract

Functional selectivity in the context of serotonin 2A (5-HT 2A ) receptor agonists is often described as differences psychedelic compounds have in the activation of Gq vs β-arrestin signaling in the brain and how that may relate to inducing psychoactive and hallucinatory properties with respect to each other. However, the presence of 5-HT 2A receptors throughout the body in several cell types, including endothelial, endocrine, and immune-related tissues, suggests that functional selectivity may exist in the periphery as well. Here, we examine functional selectivity between two 5-HT 2A receptor agonists of the phenylalkylamine class: ( R )-2,5-dimethoxy-4-iodoamphetamine [( R )-DOI] and ( R )-2,5-dimethoxy-4-trifluoromethylamphetamine [( R )-DOTFM]. Despite comparable in vitro activity at the 5-HT 2A receptor as well as similar behavioral potency, ( R )-DOTFM does not exhibit an ability to prevent inflammation or elevated airway hyperresponsiveness (AHR) in an acute murine ovalbumin-induced asthma model as does ( R )-DOI. Furthermore, there are distinct differences between protein expression and inflammatory-related gene expression in pulmonary tissues between the two compounds. Using ( R )-DOI and ( R )-DOTFM as tools, we further elucidated the anti-inflammatory mechanisms underlying the powerful anti-inflammatory effects of certain psychedelics and identified key mechanistic components of the anti-inflammatory effects of psychedelics, including suppression of arginase 1 expression.

References

42